Sanofi Pasteur, a Sanofi Company
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sanofi Pasteur, a Sanofi Company sits in the top decile of US sponsors by registered trial count (#190 of 15,742 sponsors by registered trial count).
Sanofi Pasteur, a Sanofi Company: 153 sponsored US clinical trials, 3 recruiting.
Sanofi Pasteur, a Sanofi Company sponsors 153 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 132 completed. 71 of these trials are in Phase 3-4 (later-stage) and 67 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Influenza, with 16 trials.
Top-decile sponsor footprint
Sanofi Pasteur, a Sanofi Company ranks in the top decile of sponsors by registered trial count (#190 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
132 of 144 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
153 total, page 1 of 4
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
NCT07013747
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
NCT06316297
Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
NCT04843111
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
NCT06838000
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
NCT06744205
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06736041
Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older
NCT06727058
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654
Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
NCT04942210
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
NCT06641180
Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age
NCT06582056
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
NCT06397768
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
NCT06361875
BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
NCT06325332
Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
NCT06252285
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
NCT06237296
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
NCT06134648
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
NCT06128733
Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers
NCT05964582
Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
NCT05687279
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
NCT05650554
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
NCT05624606
Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older
NCT05639894
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years
NCT05513391
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
NCT05608005
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
NCT05513053
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older
NCT05553301
Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
NCT05426174
Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older
NCT06118151
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
NCT05050318
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
NCT04969276
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
NCT04904549
Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants
NCT04825223
Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older
NCT04798027
Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
NCT04762680
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
NCT04491877
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
NCT04551677
Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age
NCT04544267
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
NCT04537208
Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects
NCT04451954
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
NCT04398706
Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
NCT04222985
Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults
NCT04142086
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age
NCT04144179
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
NCT04142242
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
NCT04109222
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
NCT04084769
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)
NCT06698198
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
NCT03698279
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
NCT03691610
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 36 |
| Phase 3 | 33 |
| Phase 4 | 38 |
Therapeutic Areas
What is open in the Sanofi Pasteur, a Sanofi Company pipeline
3 recruiting of 153 indexed (2% open); 132 completed (86%).
Phase mix: 71 late (III/IV) vs 67 early (I/II) (balanced across stages).
Top condition: Influenza (16 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sanofi Pasteur, a Sanofi Company: open-pipeline peers nationwide
Peers matched on 153 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Sanofi Pasteur, a Sanofi Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 153 trials (± recruiting share)
- Gynecologic Oncology Group · 154 trials · 1% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Galderma R&D · 158 trials · 4% recruiting
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
Sponsors near 2% open enrollment (± trial volume)
- PTC Therapeutics · 2% recruiting · 52 trials
- Spectrum Pharmaceuticals · 2% recruiting · 52 trials
- Carelon Research · 2% recruiting · 50 trials
- Société des Produits Nestlé (SPN) · 2% recruiting · 53 trials
Related
What to do with this Sanofi Pasteur, a Sanofi Company page
153 registered trials is a research-attention snapshot, not an endorsement of Sanofi Pasteur, a Sanofi Company or any single study.
- 3 of Sanofi Pasteur, a Sanofi Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Influenza is the condition Sanofi Pasteur, a Sanofi Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Influenza trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sanofi Pasteur, a Sanofi Company pipeline card: 153 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.